The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy

54 patients with idiopathic dilated cardiomyopathy (DC). Group A (n=27) treated for primary prevention (high risk of sudden death with at least two criteria: LVEDD ≥70 mm, LVEF ≤30%, non-sustained VT, disease duration ≥48 months, family history of sudden death). Group B (n=27) treated for secondary prevention (previous sustained VT/fibrillation or syncope).

Implantable cardioverter defibrillator (ICD) for primary prevention

Implantable cardioverter defibrillator (ICD) for secondary prevention

Rate of appropriate intervention (AI) at 12 monthshard clinical